fbpx

The Max Foundation Creates Subsidiary Organization, MaxAid, to Further Mission

Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.

From its launch, MaxAid will host our collaboration with Novartis, a leading global healthcare company, around humanitarian access to their medicines Glivec® and Tasigna® in a joint initiative. In the future similar contributions from other partnering companies may also be received by MaxAid.

“The advent of MaxAid is exciting for The Max Foundation because it enables us to take our operational work to the next level,” says Paula Boultbee, Chair of the Board for The Max Foundation.  She continues, “By launching MaxAid, we accomplish yet another strategic milestone for The Max Foundation in our role as a bridge to access for people facing cancer currently without treatment in lower resource settings around the world.”

This positive step of launching MaxAid in 2017 promises to keep us well positioned to decrease avoidable cancer deaths in the least developed countries and help people around the world to face cancer with dignity and hope.

See All News

The Max Foundation (Max) is a global health nonprofit organization dedicated to accelerating health equity. For more than 25 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope. Learn more at www.themaxfoundation.org

Related Articles

  • The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

    Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….

  • Welcoming our New Vice President of Development

    The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.

  • Celebrating One Year of Spot On CML

    Celebrating One Year of Spot On CML

    The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.